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Received: 3 October 2021
Accepted: 29 November 2021
Published: 30 November 2021
Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional affil-
iations.
Copyright: © 2021 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
1 George Washington University Hospital, Washington, DC 20037, USA; margarethousermd@gmail.com
2 George Washington University Medical Faculty Associates, Washington, DC 20037, USA;
davidbarreto80@gmail.com (D.B.); amehta@mfa.gwu.edu (A.M.)
* Correspondence: rbrem@mfa.gwu.edu
Abstract: Magnetic resonance imaging (MRI) is the most sensitive exam for detecting breast cancer.
The American College of Radiology recommends women with 20% or greater lifetime risk of devel-
oping breast cancer be screened annually with MRI. However, other high-risk populations would
also benefit. Hartmann et al. reported women with atypical hyperplasia have nearly a 30% incidence
of breast cancer at 25-year follow-up. Women with dense breast tissue have up to a 4-fold increased
risk of breast cancer when compared to average-risk women; their cancers are more likely to be
mammographically occult. Because multiple cohorts of women are at high risk for developing breast
cancer, there has been a movement to develop an abbreviated MRI (abMRI) protocol to expand the
availability of MRI screening. Studies on abMRI effectiveness have been promising, with Weinstein
et al. demonstrating a cancer detection rate of 27.4/1000 in women with dense breasts after a negative
digital breast tomosynthesis. Breast MRI is also used to evaluate the extent of disease as part of
preoperative assessment in women with newly diagnosed breast cancer, and to assess a patient’s
response to neoadjuvant chemotherapy. This paper aims to explore the current uses of MRI and
propose future indications and directions.
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1. Introduction
Breast cancer is the most common cancer in women globally and the second leading
cause of cancer deaths. In the United States, there are over 250,000 new cases of breast cancer
annually with over 46,000 women dying of the disease [1]. Over the past two decades,
the death rate from breast cancer has decreased by over 40%, a monumental achievement,
due to the combination of improved detection as well as improved, increasingly targeted
therapies [1]. When breast cancer is detected early, over 95% of women survive more
than five years. Indeed, the detection and treatment of an earlier breast cancer is not only
associated with improved outcome, but also with a lower intensity of care, meaning less
aggressive therapy and less extensive surgery. Therefore, it is critical that every woman
has the optimal chance at detection of early, curable breast cancer.
Initially, breast cancer screening was performed with mammography alone. However,
as we increasingly understand breast cancer risk, we have been increasingly implementing
risk-based screening, that is, screening based on an individual woman’s risk of developing
breast cancer. The use of mammography alone is no longer be the optimal approach for the
detection of earlier, more curable breast cancer. Depending on a woman’s individualized
risk, optimal screening is tailored and may include mammography, ultrasound and MRI as
well as exciting, emerging technologies such as ultrasound tomography [2] or abbreviated
breast MRI. Even so, the mainstay of breast cancer screening remains mammography, and
it is a critical and necessary component for virtually all women.
Specific recommendations for mammographic screening vary widely. The Ameri-
can Society of Breast Surgeons and American College of Radiology recommend annual
screening beginning at age 40 for all women at average risk of breast cancer [3,4], the
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American Cancer Society (ACS) says one should consider beginning screening at 40, with
recommendations for annual screening at 45 to 54 and annual or biennial screening there-
after [5], and the United States Preventative Services Task Force recommends biennial
screening from ages 50–74 [6]. While many varying recommendations exist, the data
definitively demonstrates that annual mammography beginning at age 40 results in the
most lives saved compared to other proposed screening protocols [4]. These recommen-
dations are for women at average risk of breast cancer. In women with a first degree
relative or second degree relatives with breast cancer, the ACR recommends beginning
annual screening mammography 5–10 years earlier than the age that the family member
developed breast cancer [4]. The ACS recommends that women at substantially increased
risk, defined as a 20% lifetime risk of breast cancer or greater, undergo annual screening
contrast-enhanced breast MRI in addition to annual mammography, as MRI remains the
most sensitive imaging modality available for the detection of breast cancer [7]. This group
of high-risk women includes those with BRCA 1 or 2 mutations, untested first-degree
relatives of BRCA-positive patients, history of chest radiation for Hodgkin’s lymphoma
between the ages of 10 and 30 years, and women with PalB2 mutations and other genetic
syndromes associated with elevated breast cancer risk [7].
As the most sensitive exam, breast MRI has many clinical uses in addition to screening.
This paper aims to outline and explore the current indications for breast MRI, including as a
tool for screening high-risk populations, evaluating extent of disease as part of preoperative
assessment in women with newly diagnosed breast cancer, and assessing a patient’s
response to neoadjuvant chemotherapy. We will also propose future indications for breast
MRI, such as using MRI as a biomarker for breast cancer risk and treatment response,
as well as implementing abbreviated protocol breast MRI programs to expand access of
screening breast MRI to those who would benefit from it.
2. High-Risk Screening
Mammography, the mainstay of breast cancer screening, is an excellent examination
that has been critical in reducing breast cancer mortality; screening mammography has
been proven to reduce mortality by 20–35% [8]. Yet, mammography is an imperfect
examination. Although the overall sensitivity of mammography for the detection of breast
cancer is 85% [9], the sensitivity of mammography is substantially reduced in women with
dense breasts, with sensitivities as low as 45–65% [10]. In women with BRCA mutations, the
sensitivity of mammograms is decreased and has been reported to be 33% [11], significantly
lower than the overall sensitivity of mammography [9]. Because of mammography’s
limitations, additional technologies have been developed to increase the detection of
mammographically occult breast cancer.
In women with dense breasts, screening breast ultrasound has been utilized to detect
mammographically occult breast cancers. Importantly, studies have shown that the mam-
mographically occult cancers detected with screening breast ultrasound are most frequently
small, invasive, node-negative cancers [12,13]. These cancers are critical to detect before
they advance to node-positive and possibly metastatic disease. Studies have demonstrated
that screening breast ultrasound can detect approximately 25% more cancers in women
with dense breast tissue than mammography alone [14]. Screening breast ultrasound,
whether handheld or automated, has been increasingly incorporated in clinical practice to
optimize the detection of these mammographically occult but clinically important breast
cancers. There are exciting technological advances in ultrasound, such as the development
of ultrasound tomography, which utilizes ultrasound and sound speed to improve both the
sensitivity and specificity of breast cancer detection [2]. This, and likely other technologies,
should help with the ongoing issue of high false-positive rates found with screening breast
ultrasound, as well as increase the detection of mammographically occult breast cancers.
Women with a BRCA mutation have a 60–85% cumulative lifetime risk of developing
breast cancer [15]. The sensitivity of MRI for the detection of breast cancer in this high-risk
population ranges from 75–100% [7]. Studies have demonstrated that in BRCA-positive
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women, 44.7% of cancers are not detectable with mammography and are detected with MRI,
whereas 2.1% of cancers are detected by mammogram and not identified with MRI [16].
Furthermore, MRI detected cancers in BRCA-positive women have a better prognosis than
those detected with mammography, in that they are more frequently node -negative [15].
A study by Kriege et al. demonstrated that MRI not only detected cancers not visible
with mammography and clinical breast exam, but over half were smaller than 10 mm
and only 1 case of the 20 invasive cancers in this study was associated with node posi-
tivity [15]. Lo et al. demonstrated statistically significant greater cancer detection rates
(CDR) with MRI when compared to mammography in high-risk women; MRI detected
21.8 cancers per 1000 women screened whereas mammography detected 7 per 1000 women
screened [17]. Sippo et al. confirmed a high MRI CDR in patients with BRCA mutations,
at 26 per 1000 women screened [18]. The robust data obtained with numerous studies
investigating the use of screening breast MRI in women at markedly increased risk of
breast cancer demonstrates that annual screening with MRI detects earlier, more frequently
node-negative and more likely curable breast cancer. As a result, the ACS and numerous
other societies agree that annual screening with MRI for women at the highest risk of breast
cancer is not only recommended but strongly advised (Figure 1).
Figure 1. 28-year-old woman with a known BRCA 2 genetic mutation presented for her baseline
annual high-risk screening MRI. Axial contrast-enhanced T1-weighted fat-suppressed image shows
a 1.4 × 1.3 × 1.2 cm rim enhancing mass in the upper inner left breast (solid white arrow). This
was a biopsy-proven grade 3 invasive ductal carcinoma. There is also a 3.1 × 3.6 × 2.1 cm rim
enhancing mass with central necrosis in the upper outer right breast (white dashed arrow). This was
also biopsy-proven grade 3 invasive ductal carcinoma.
It is important to note that the population of women at increased risk of breast cancer,
for whom MRI is critically important, has been expanding. Initially, the recommendation
for annual screening with MRI was only for those with a genetic mutation, where 27 cancers
per 1000 women screened with MRI were detected [15]. Further studies in women with a
personal history of breast cancer demonstrated a CDR ranging from 10 to 29 cancers per
1000 women screened [19–24]. In addition, women with high-risk breast lesions, such as
atypical lobular or ductal hyperplasia, have a CDR of 13 per 1000 women when screened
with MRI [25]. Up to 30% of patients diagnosed with atypical hyperplasia develop breast
cancer after 25 years [26]. Studies have demonstrated that these women also benefit
with MRI screening, with a CDR of 15 cancers per 1000 women screened [18]. Sippo and
colleagues reported no difference in CDR for screening breast MRI examinations performed
in patients with a personal history of breast cancer (12 per 1000 examinations) or high-risk
lesion (15 per 1000 examinations), compared with those performed for BRCA mutation or
history of chest radiation (26 per 1000 examinations; p = 0.14 and p = 0.18, respectively) [18].
Women with dense breast tissue are at moderately increased risk of breast cancer
(15–20% lifetime risk). Forty percent of women in the US have dense breasts [27]. Women
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with dense breast tissue have up to 4.6-fold increased risk of developing breast cancer
when compared to average risk women [28]. In addition, the sensitivity of mammography
in women with dense breast tissue is significantly decreased, with reports as low as 45%.
As a result, cancers are usually larger and more frequently node-positive at the time of
diagnosis [29]. Additionally, the frequency of interval cancer detection, that is, cancer
detected within a year of a normal screening mammogram, is significantly higher in
women with dense breast tissue. It is well-known that interval cancers have a poorer
prognosis. Therefore, supplemental screening MRIs in women with dense breasts and
normal mammograms has been suggested and investigated. A recent study from the
Netherlands investigating the impact of interval cancers in women with dense breast tissue
who underwent screening MRI and demonstrated a significant reduction in interval cancers
with screening MRI [30]. Indeed, half the number of interval breast cancers were detected
in women with dense breasts who underwent screening MRI; 2.5 cancer per 1000 screened
with MRI, versus 5.0 per 1000 screened with mammography alone [30]. This reduction in
interval cancers, which is statistically significant, demonstrates that supplemental screening
MRI in women with dense breasts is beneficial. Additionally, this study demonstrated an
unexpectedly high CDR when MRI was used to screen women with dense breast tissue
(16.5 per 1000 screenings) demonstrating the benefit of screening MRI in women with dense
breast tissue [30].
MRI screening has political implications as well. In the United States, screening
mammography is covered without a co-pay or deductible as part of the Affordable Care
Act (ACA); screening MRI is not. It is not uncommon for insurance to reject MRI screening,
especially in women who do not have a deleterious genetic mutation. Efforts are underway
to facilitate the approval of MRI screening. With the robust evidence demonstrating the
significant benefit of screening MRI in women with a personal history of breast cancer, a
history of high-risk lesions, and even in women with dense breast tissue, Pennsylvania
Governor Tom Wolf signed Senate Bill 595 in June 2020 which requires insurance coverage
of supplemental breast cancer screening with MRI in women with extremely dense breasts
(BIRADS D) and in women with heterogeneously dense breast tissue (BIRADS C) and one
other high-risk factor [31]. It is hopeful that additional states will follow suit and facilitate
the approval of screening MRI by eliminating the financial barrier to obtaining screening
MRI in women at increased risk for breast cancer.
3. MRI Evaluation of Newly Diagnosed Breast Cancer
In women with newly diagnosed breast cancer, preoperative staging is required to
assess disease extent to optimize treatment strategy. Assessment of locoregional metastases
into the axillary, internal mammary and supraclavicular nodal basins is critical information
for surgical and treatment planning. Preoperative breast MRI plays an important role in
delineating the extent of the primary tumor and diagnosing multicentric and contralateral
disease, as well as in the evaluation of local nodal metastases and chest wall involvement.
Studies have demonstrated that when women with newly diagnosed breast cancer are
evaluated with MRI, additional foci of disease are identified in 10% of women: 7% in
the ipsilateral breast and 3% in the contralateral breast [32]. Of the contralateral cancer
diagnosed on preoperative MRI, most are less than 1 cm in size, and approximately one-
third are ductal carcinoma in situ (DCIS) (Figure 2).
A meta-analysis by Plana et al. [33] demonstrated that additional disease was found in
the ipsilateral breast in 20% with a positive predictive value (PPV) (of lesions undergoing
biopsy) of 67%, and in approximately 20%, these additional findings impacted surgical
planning. Brennan et al. performed a meta-analysis of 22 studies which reported suspicious
MRI detected findings in the contralateral breast of women with newly diagnosed breast
cancer, and found additional foci in 9.3% of women, with a PPV (of lesions undergoing
biopsy) of 47.9% yielding a cancer detection rate of 4.1% in the contralateral breast (32). In a
retrospective study, Benveniste et al. demonstrated that in 76 patients diagnosed with pure
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DCIS who underwent preoperative MRI staging, approximately 8% had additional foci of
cancer (6.6% DCIS and 1.3% invasive breast cancer), all in the contralateral breast [34].
Figure 2. 75-year-old woman presented for annual screening evaluation. Mammogram demonstrated a left breast asymmetry
(not shown) which prompted further workup. (a) Left breast ultrasound in radial projection at the 10 o’clock axis 3 cm
from the nipple demonstrates a suspicious 0.5 × 0.6 × 0.4 cm hypoechoic antiparallel mass with irregular margins and
posterior acoustic shadowing (arrow), corresponding to the mammographic abnormality. Ultrasound guided biopsy yielded
invasive ductal carcinoma, mucinous type. (b) MRI was performed to evaluate the extent of disease; axial contrast-enhanced
T1-weighted fat-suppressed image demonstrates a separate 0.7 × 0.5 cm enhancing irregular mass in the lower inner
quadrant of the contralateral right breast (dashed arrow). This was biopsied under MRI guidance and yielded invasive
ductal carcinoma, mucinous type. The known left breast cancer is not shown.
Given its sensitivity, MRI is the most powerful tool to assess breast cancer and a
significant number of women are found to have disease that was occult on mammography
and ultrasound. This information aids in surgical planning with the goal of decreasing
positive margins and re-excision rates. This is particularly true in women with pure DCIS or
known invasive cancer with an extensive DCIS component [35]. In a cohort of 593 women
who underwent breast surgery, Kuhl et al. reported that more than half of DCIS associated
with invasive cancer was detected only with MRI, compared to FFDM and radiologist-
performed US [35]. In the same study, positive margins were demonstrated in only 3.7%
of the cases after MRI imaging and MRI-guided biopsy/bracketing, which is significantly
lower than positive margin rates reported after conventional assessment in similar cohorts,
ranging from 20.0–40.0% [35–37]. Additionally, women with invasive lobular carcinoma
benefit from preoperative MRI. Lobbes et al. reported that preoperative MRI in women
with ILC results in a significantly lower risk of positive margins without a concomitant
increase in mastectomies [38].
The use of preoperative MRI in all newly diagnosed patients is still controversial
and guidelines differ among institutions. Although there is solid evidence that MRI
demonstrates disease that is not seen by conventional modalities, it is still unclear if that
translates to better patient outcomes, specifically disease-free survival and overall sur-
vival. Moreover, studies have shown that women with newly diagnosed breast cancer
who undergo MRI have a higher rate of mastectomies. Preoperative MRI may be most
beneficial in patients with triple-negative breast cancer (TNBC), invasive lobular cancers, or
patients who undergo breast conservation without radiation therapy. Wang et al. demon-
strated that preoperative MRI improved breast cancer survival in women who underwent
breast-conserving without radiation therapy [39]. Given that use of preoperative MRI is
controversial, a multicenter international study with more than 7000 enrolled patients is cur-
rently underway to investigate and compare the clinical outcomes in women undergoing
versus not undergoing preoperative breast MRI [40].
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Although many trials have demonstrated improved accuracy as well as margin assess-
ment with MRI, studies have also shown that preoperative MRI results in an increased rate
of mastectomies. A meta-analysis of 19 studies by Houssami et al., reported that preopera-
tive MRI was associated with a 1.4 increased odds ratio for mastectomy, and MRI was also
associated with increased odds ratio (1.91) of a contralateral prophylactic mastectomy [41].
The increased rate of mastectomy following preoperative MRI must be considered when
clinical decisions regarding preoperative MRI are made. Even so, at our institution, nearly
all women with newly diagnosed breast cancer undergo MRI for assessment of extent of
disease, surgical planning and reducing the need for re-excision, as we believe the benefit
outweighs the risks. Figure 3 shows a preoperative MRI demonstrating extent of the newly
diagnosed breast cancer. Skin and posterior chest wall involvement, as well as satellite
lesions and metastatic sternal lesions, were first identified in this study, resulting in change
in management. The patient received preoperative chemotherapy to attempt to reduce
disease burden before surgery (Figure 3). Furthermore, at our institution the use of margin
assessment tools, such as MarginProbe [42], further allows the surgical team to implement
available strategies to decrease the need for re-excision.
Figure 3. 55-year-old woman presented with a palpable breast mass and asymmetric breast size. Mammogram and
ultrasound showing a large mass are not shown. MRI was performed to evaluate for extent of disease. (a) Axial contrast-
enhanced T1-weighted fat-suppressed image demonstrates a 13 cm ring-enhancing centrally necrotic lateral right breast
mass (solid arrow). Additional rim-enhancing centrally necrotic satellite lesions are noted at the medial aspect of the
breast (dashed arrow). (b) Sagittal contrast-enhanced T1-weighted fat-saturated image demonstrates a large irregular
heterogeneously enhancing right breast mass invading the right pectoralis muscle (arrow). The edge of the normal pectoralis
muscle (M) is seen superiorly. Diffuse skin thickening and enhancement (*) is compatible with skin involvement, and satellite
lesions (dashed arrow) are redemonstrated. p demarcates the posterior aspect of the image. (c) Axial contrast-enhanced
T1-weighted fat-saturated image demonstrates abnormally enlarged and enhancing right axillary lymph nodes (arrow) and
an enhancing metastatic bone lesion in the sternum (dashed arrow). Right breast skin thickening (*) is again noted.
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4. Response to Neoadjuvant Chemotherapy
Neoadjuvant chemotherapy (NACT) is the preferable approach in patients with lo-
cally advanced (stage II or III) and TNBC. Long-term outcomes for patients receiving
NACT versus adjuvant chemotherapy were demonstrated in a patient-level meta-analysis
conducted by the Early Breast Cancer Trialists’ Collaborative Group [43]. When com-
pared with adjuvant chemotherapy, NACT was associated with an increased frequency of
breast-conserving surgery (65% vs. 49%) and an equivalent risk of both distant recurrence
(15-year risk 38.2% vs. 38.0%) and breast cancer mortality (34.4% vs. 33.7%) [43]. However,
NACT was also associated with more frequent local recurrence than adjuvant chemother-
apy (15-year local recurrence 21.4% vs. 15.9%) [43]. This difference may be due to more
frequent breast-conserving therapy in women with TNBC. Of note, patients undergoing
NACT who achieve pathologic complete response (pCR), defined as the absence of resid-
ual invasive cancer on pathologic evaluation following surgery, have excellent long-term
survival outcomes [44–46]. More than half of the patients with HER2-amplified tumors
achieved pCR [47]. With the increasing use of NACT, methods to assess the effectiveness
of neoadjuvant chemotherapy are needed.
It is important to assess response to NACT as early as possible during therapy, as a
poor response can trigger a change in the chemotherapeutic regimen. There are multiple
methods for evaluating response to neoadjuvant chemotherapy. Initially, response to
neoadjuvant chemotherapy relied on physical examination along with conventional breast
imaging, i.e., mammogram, and US. Studies have demonstrated a moderate correlation
between pCR and physical examination, mammography and ultrasound reported at 57%,
74% and 79%, respectively [48]. More recently, studies have demonstrated greater accuracy
of MRI in assessing response to NACT with a reported sensitivity of 88–89% (Figure 4) [49].
The ability of MRI to assess response to NACT is based on a number of factors,
including tumor molecular subtype (less accurate in luminal, and greater accuracy in triple-
negative tumors and HER-2 positive tumors) [50], as well as type of chemotherapy used.
MRI has a greater likelihood of underestimating residual disease in patients treated with
antiandrogenic drugs [51] and more accurate with regimens that do not include taxanes.
Schrading et al. demonstrated that the use of taxanes resulted in 66.7% false-negative MRI
findings in patients with residual disease, versus 20% false-negatives rate in patients treated
with multiagent chemotherapy without taxanes [52]. Additionally, Chen et al. have shown
that MRI can overestimate residual disease in 6–19% of cases, and underestimate in 7–28%
of cases [53]. According to Reig et al., causes of overestimation of residual disease include
fibrosis/treatment changes, necrotic tumor and residual benign masses, whereas tumors
with nonmass morphology, tumors with nonconcentric shrinkage, antiandrogenic therapy
and late-enhancing foci tend to demonstrate underestimation of residual disease [54].
MRI following neoadjuvant therapy can also be helpful in downstaging biopsy-proven
metastatic axillary lymph node, with some studies demonstrating a sensitivity of 61–
72% [55]. Although imperfect, MRI is currently the most accurate imaging modality to
assess response to neoadjuvant chemotherapy, and particularly when response is concentric,
can be quite accurate.
Recently, a novel approach to assess response to NACT has been reported. Duric and
colleagues reported accurate assessment of early response to neoadjuvant chemotherapy
utilizing ultrasound tomography [56]. This approach detected response early in the course
of neoadjuvant chemotherapy, which may allow for earlier intervention for chemother-
apeutic regimens with less-than-optimal response. Additionally, this approach does not
require injection of contrast. Although additional studies are needed for further evaluation,
this approach is exciting and has potential to accurately evaluate response to neoadjuvant
chemotherapy early in the course of treatment.
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Figure 4. 47-year-old woman with a right breast invasive ductal carcinoma. (a) Prechemotherapy axial contrast-enhanced
T1-weighted fat-suppressed MRI shows a 2.7 × 2.5 × 2.2 cm irregular mass with a thick rim of enhancement in the
upper outer right breast (arrow), compatible with the known invasive ductal carcinoma. (b) Prechemotherapy axial
contrast-enhanced T1-weighted fat-suppressed MRI shows an area of non-mass-like enhancement compatible with DCIS
(edges demarcated by (*) located posterior to the mass (arrow). (c) Prechemotherapy maximum intensity projection image
demonstrates a right breast mass (arrow) with associated enhancing right axillary and intramammary lymphadenopathy
(dashed arrows), compatible with metastatic disease. (d) Postchemotherapy contrast-enhanced T1-weighted fat-suppressed
MRI shows resolution of the right breast mass. Susceptibility artifact from the biopsy clip is seen in the tumor bed (arrow).
The area of non-mass-like enhancement has also resolved (not shown). (e) Postchemotherapy maximum intensity projection
image demonstrates resolution of the previously seen large right breast mass (solid arrow in tumor bed). The right axillary
and intramammary lymph nodes are redemonstrated but have decreased in size (dashed arrow).
5. Imaging Biomarkers
Breast cancer can be identified on MRI by its pattern of enhancement after the admin-
istration of intravenous contrast. Because malignancies undergo uncontrolled angiogenesis
in patterns different from benign breast tissue, breast cancer generally appears as a rel-
atively bright focus of enhancement on MRI. Some benign as well as high-risk lesions
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also enhance, and kinetic information of MRI contrast uptake and excretion from tissues
can help differentiate benign and malignant lesions. It is important to note that normal
fibroglandular breast tissue enhances, a phenomenon known as background parenchymal
enhancement (BPE), albeit generally at a slower rate than cancer or high-risk lesions. BPE
is thought to reflect the background physiologic activity of a woman’s breast tissue and is
affected by each woman’s unique vascular and hormonal factors, exposure to endogenous
and exogenous hormones, and use of endocrine therapy [57]. Menopausal status, men-
strual cycle, hormone replacement therapy, and tamoxifen use may impact the extent of
BPE in women.
Background parenchymal enhancement is characterized in the breast imaging (BIRADS)
lexicon as minimal, mild, moderate, and marked [58]. Moderate or marked BPE can hinder
breast cancer detection due to the increased background uptake. Similar to mammography
in a patient with dense breasts, the interpreting radiologist is looking for a bright cancer
in a background of enhancement, i.e, a bright background [59]. To mitigate the decrease
in sensitivity of MRI, especially in women with substantial BPE, it is recommended that
women undergo MRI examinations when performed for screening during the second week
(follicular phase) of their menstrual cycle, to decrease endogenous hormonal influence on
their BPE [60].
Increased estrogen exposure is a known risk for breast cancer due to tumorigenesis
via estrogen receptors. BPE is positively affected by both endogenous and exogenous
estrogen. Studies have demonstrated a positive correlation between BPE and breast cancer
risk [59,60]. Moderate or marked BPE is associated with a higher risk of developing breast
cancer compared to women with minimal or mild BPE (odds ratio of 2.1) [61]. A study by
Arasu et al. found BPE to be associated with increased risk of breast cancer independent of
mammographic breast density [62]. Given these findings, it is likely that future risk models
will consider including BPE in risk assessments and qualification for high-risk screening
with MRI.
Tamoxifen and other estrogen receptor modulators are used both as adjuvant therapy
for estrogen receptor / progesterone receptor (ER/PR) positive breast cancer and as a risk
reduction strategy in women at increased risk of breast cancer. Studies have demonstrated
up to a 50% decrease in incidence of cancer when tamoxifen is used for risk reduction [63].
When MRI is performed in women undergoing tamoxifen therapy, a variable decrease in
BPE is noted. Studies have begun to investigate whether the resultant decrease in BPE
following tamoxifen therapy may reflect the individualized effectiveness of the therapy. It
is hypothesized that the imaging manifestation of the antiestrogenic effect of tamoxifen may
well be reflected in the impact on BPE. However, up to 32% [64] of patients on tamoxifen
therapy do not have the expected decrease in BPE. It is possible that the lack of decrease
in BPE may reflect a lesser antiestrogenic effect. Patients with little or no impact on BPE
when on tamoxifen therapy may not be benefiting. Given that tamoxifen has significant
side effects including deep venous thrombosis, pulmonary emboli, stroke, and endometrial
cancer, the benefits may not outweigh the risks in this subset of patients. However, this
is currently hypothetical and additional studies are underway to further investigate the
possibility of modulating risk reduction tamoxifen therapy based on effect of BPE.
Molecular breast imaging (MBI), also known as breast-specific gamma-imaging (BSGI),
is another sensitive physiologic imaging modality used to detect breast cancer [65]. This
exam uses intravenous injection of 99mTc-sestamibi, a nuclear radiotracer, to physiologically
differentiate between benign and malignant breast tissue. MBI/BSGI detects cancer with
a sensitivity and specificity of up to 96% and 80%, respectively [66] and can increase
detection of mammographically occult cancers by up to 1.7% of women at increased risk
of breast cancer [65]. Patients who cannot undergo MRI, whether due to obesity, inability
to lay flat, MRI contrast allergy, renal insufficiency, claustrophobia, or metallic hardware
incompatibility, can benefit from physiologic imaging with BSGI.
Background parenchymal uptake (BPU) is the MBI/BSGI equivalent of BPE in MRI,
and is defined as the 99mTc-sestamibi uptake within normal fibroglandular tissue. Studies
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have shown elevated BPU is associated with increased breast cancer risk [67]; BPU can
therefore act as a nuclear medicine biomarker for predicting risk. Additionally, just as
tamoxifen can decrease BPE on MRI, it can also decrease BPU on MBI/BSGI. Noting a
patient’s change in BPU with tamoxifen therapy may reflect the effectiveness of tamoxifen
and influence treatment decisions with estrogen receptor modulators. Additional studies
are needed to further define the use of assessing BPE on management decisions including
tamoxifen therapy.
6. Abbreviated Breast MRI
Given that MRI is the most sensitive tool to detect cancer, there has been a movement to
expand access to MRI screening. Due to its cost, full-protocol, dynamic contrast-enhanced
breast MRI (fpMRI) has traditionally been offered as a screening tool only to women at
the highest risk for breast cancer [68]. An fpMRI, which includes multiple phases of axial
T1-weighted pre- and post-contrast images with and without fat suppression, axial T2 or
STIR, and a sagittal delayed post-contrast sequence, takes 45–60 min to acquire, in addition
to the time required to prepare and position the patient for the examination.
Abbreviated breast MRI (abMRI) has been developed to increase access and decrease
the cost of screening breast MRI. AbMRI consists of fewer sequences requiring a shorter
time and lower cost for the examination. Multiple studies have investigated whether abMRI
can replace a fpMRI in the screening setting. A prospective study by Kuhl et al. [69] demon-
strated that abMRI was equal to fpMRI in sensitivity and specificity. In addition, their study
demonstrated that abMRI significantly decreased MRI acquisition time and average time
for radiologist interpretation without sacrificing the examination’s specificity or positive
predictive value (abMRI 94.3% and 24.4%, respectively versus fpMRI 93.9% and 23.4%,
respectively) [69]. The abMRI negative predictive value was 99.8% [69]. Osei et al. found
comparable cancer detection and patient recall rates for abMRI vs. fpMRI, while abMRI
significantly decreased the radiologist’s time for interpretation [70]. Weinstein et al. demon-
strated screening abMRI resulted in a CDR of 27.4/1000 in women with dense breasts after
a negative digital breast tomosynthesis [71]. This is in contrast to the reported CDR of
an fpMRI in women with dense breasts of 16.5/1000 [30]. Although quite a number of
studies have demonstrated the benefits of abMRI [72,73], a universal abMRI protocol has
not yet been developed. It is hoped that once a protocol has been standardized, women
with dense breasts and those at intermediate risk for breast cancer will have access to MRI
as the most sensitive screening tool, rather than only patients at the highest risk [30,72,74].
An example abMRI protocol, as outlined in the American Journal of Roentgenology Expert
Panel Review [74], is shown in Figure 5.
A major barrier to implementation of a population-wide abMRI screening program
has been cost. The average insurance reimbursement for a fpMRI is $1084. Studies
have demonstrated that 8% of screening MRIs detect a suspicious lesion (BIRADS 4 or 5)
requiring additional workup and possible biopsy [75]. By way of contrast, abMRI, while
not covered by insurance, can cost as low as $299. The lower cost is possible due to the
decreased examination time, allowing for a greater volume and a shorter interpretation
time. It would be optimal to further decrease the MRI time by facilitating quicker patient
preparation. Current MRI machines are not designed for high patient throughput. Time
preparing the scanner and maneuvering the patient into the magnet takes longer than
abMRI image acquisition itself [76]. Screening-focused MRI magnets would allow for even
greater throughput, more widespread availability, and lower cost for this lifesaving tool in
the high-risk population. Ultimately, these new machines could be used for other types of
abMRIs tailored to answer specific clinical questions [76].
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Figure 5. Example protocol of an abMRI. 61-year-old woman presented for screening MRI. (a) Maximum intensity projection
image illustrates a 3.8 × 3.2 × 4.6 cm rim enhancing centrally necrotic mass in the right breast (arrow). Biopsy of this
lesion yielded invasive ductal carcinoma. The enhancing axillary lymph nodes (dashed arrow) are asymmetric compared
to the contralateral side, and was biopsy-proven metastatic disease. The right breast is asymmetrically decreased in size.
(b) Contrast-enhanced axial T1-weighted fat-suppressed image demonstrates the same rim-enhancing mass in the right
breast (arrow). (c) Contrast-enhanced axial T1-weighted fat-suppressed image demonstrates an irregular 2.8 × 2.0 cm
spiculated mass, compatible with metastatic lymph nodes (dashed arrow). (d) Contrast-enhanced axial T2-weighted fat-
suppressed image demonstrates the same right breast mass (arrow) with associated skin thickening (*), compatible with skin
involvement. Associated fibrosis (F) results in nipple retraction, indicating nipple involvement. (e) Non-contrast-enhanced
T1-weighted axial image without fat suppression redemonstrates the mass (arrow), skin thickening (*) and fibrosis (F)
resulting in nipple retraction. In addition to the above sequences, a full protocol MRI would also include a T1-weighted
axial noncontrast image with fat suppression, at least three other dynamic axial T1-weighted post-contrast sequences, and a
sagittal delayed post-contrast sequence.
Given that the cost of abMRI can be as low as $299, which is lower than the insurance
copay for a fpMRI, some institutions have developed robust MRI high-risk screening
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programs using a self-pay model. Grimm et al. [74] recommend that institutions price their
self-pay abMRIs as low as possible, so as to not create significant healthcare disparity.
In order to implement wider use of abMRI, a standardized abMRI protocol is needed.
Future steps will likely include development of universal abMRI protocols as well as
quality measures and guidelines. Subsequent studies will undoubtedly further define the
role of abMRI in screening guidelines [76].
7. Conclusions
MRI is the most sensitive, currently available method for the detection of breast cancer.
Its indications include screening high-risk populations, evaluating women with newly
diagnosed breast cancer for extent of disease and planning surgical management, and
assessing response to neoadjuvant chemotherapy. Currently developing indications include
using abMRI to expand the availability of screening MRI to other high-risk populations.
Breast MRI may also be used as a biomarker for breast cancer risk and efficacy of tamoxifen
therapy as hormonal treatment for women with breast cancer, and as a risk reduction
strategy for women at increased risk of breast cancer.
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